Does Rallies show live market data for ACAD?

Rallies combines live market context with ticker research for ACAD, including charts, news, financials, analyst data, institutional holdings, politician trades, insider activity, and AI research where available.

ACAD (Acadia Pharmaceuticals Inc.) Stock Analysis

Acadia Pharmaceuticals Inc. (ACAD) is a publicly traded Healthcare sector company. As of May 21, 2026, ACAD trades at $21.00 with a market cap of $3.54B and a P/E ratio of 9.34. ACAD moved +2.25% today. Year to date, ACAD is -19.89%; over the trailing twelve months it is -3.41%. Its 52-week range spans $13.40 to $28.35. Analyst consensus is strong buy with an average price target of $32.77. Rallies surfaces ACAD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What is the latest ACAD stock research?

Acadia Pharmaceuticals Inc. (ACAD) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. ACAD moved +2.25% today. Analyst consensus is strong buy.

ACAD Key Metrics

Key financial metrics for ACAD
Metric	Value
Price	$21.00
Market Cap	$3.54B
P/E Ratio	9.34
EPS	$2.23
Dividend Yield	0.00%
52-Week High	$28.35
52-Week Low	$13.40
Volume	1.47M
Avg Volume	0
Revenue (TTM)	$1.10B
Net Income	$375.65M
Gross Margin	91.47%

Latest ACAD News

Acadia Q1 EPS $0.02, $268.1M Revenue Miss, $1.22B–$1.28B Outlook — May 6, 2026
Acadia Pharmaceuticals Upgraded to Buy After 25% Pullback, Maintains $29 Target — Mar 25, 2026
EU Rejects Trofinetide for Rett Syndrome, Acadia Plans Re-Examination — Mar 5, 2026
ACADIA Q4 Sales Surge to $284M, Guides $1.22–1.28B 2026 Revenue, Wolfe Sets $33 Target — Mar 2, 2026
Acadia Posts Record Q4 Revenue Growth, Announces Phase III Pipeline Starts — Feb 26, 2026

Recent ACAD Insider Trades

Kihara James sold 1.33K (~$29.02K) on May 4, 2026.
Schneyer Mark C. sold 3.51K (~$76.40K) on May 4, 2026.
Schneyer Mark C. sold 2.71K (~$60.14K) on Apr 7, 2026.

ACAD Analyst Consensus

15 analysts cover ACAD: 0 strong buy, 12 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $32.77.

Common questions about ACAD

What can I research for ACAD on Rallies?: Acadia Pharmaceuticals Inc. (ACAD) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. ACAD moved +2.25% today. Analyst consensus is strong buy.
Does Rallies show live market data for ACAD?: Rallies combines live market context with ticker research for ACAD, including charts, news, financials, analyst data, institutional holdings, politician trades, insider activity, and AI research where available.